Federal Circuit Reverses District Court Ruling of Invalidity and Upholds Rulings on Other Grounds in Favor of Finnegan Client Eli Lilly and Company
July 29, 2011
FOR IMMEDIATE RELEASE
July 29, 2011
Contact: Charles E. Lipsey, 571.203.2755
Partner
Federal Circuit Reverses District Court Ruling of Invalidity and Upholds Rulings on Other Grounds in Favor of Finnegan Client Eli Lilly and Company
WASHINGTON, DC - The U.S. Court of Appeals for the Federal Circuit reversed a district court’s ruling of invalidity for lack of enablement/utility of Finnegan client, Eli Lilly and Company’s method of use patent on Strattera® and upheld the court’s rulings of validity on other grounds and the judgment of infringement in a case involving numerous generic drug manufacturers. The Federal Circuit’s ruling in Lilly’s favor provides protection for Lilly’s Strattera® franchise through May 2017.
About Finnegan
With more than 375 intellectual property lawyers, Finnegan is one of the largest IP law firms in the world. From offices in Washington, DC; Atlanta, Georgia; Cambridge, Massachusetts; Palo Alto, California; Reston, Virginia; Brussels, Belgium; Shanghai, China; Taipei, Taiwan; and Tokyo, Japan, the firm practices all aspects of patent, trademark, copyright, and trade secret law, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com. ###
